Skip to main content
Figure 1 | BMC Endocrine Disorders

Figure 1

From: The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats

Figure 1

Body weight (A), fat mass in % of body weight (B) and leans mass in % of body weight (C) at baseline, 2 and 4 months. Rats were either sham operated and given vehicle (SHAM) or ovariectomized and given vehicle (OVX), Wyeth 14643 (WY OVX), fenofibrate (FENO OVX) or pioglitazone (PIO OVX) respectively. Data are presented as means ± SEM. a, aa,aaa = p < 0.05, p < 0.01, p < 0.001 compared to the SHAM, b,bb = p < 0.05, p < 0.01 compared to the OVX. c, cc,ccc = p < 0.05, p < 0.01, p < 0.001 compared to FENO OVX. dd,ddd = p < 0.01, p < 0.001 compared to WY OVX.

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us